Noise and Hearing

Jablon, S; Belsky, J L; Keishi, Tachikawa; Steer, A

doi:10.1097/00043764-197109000-00021

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies by several investigators failed to reveal any specific association of known oncogenes with ALL (27)(28)(29). Furthermore, extensive epidemiological studies by many investigators [e.g., a collaborative study by Greaves et al involving 20 medical centers in 18 countries (30)] failed to reveal any clear etiologic agent associated with ALL with a probable exception of the atomic bomb in Japan (31). Thus, little is known about the pathogenesis of ALL.…”

Section: Discussionmentioning

confidence: 99%

Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6.

Haruta¹,

Seon²

1986

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6(human non-T-cell and myelo-monocytic leukemia antigen/cell surface glycoprotein/immunodiagnosis) YURO Communicated by David Harker, July 10, 1986 ABSTRACT In this study, a monoclonal antibody (mAb) termed SN6 was generated by immunizing a mouse with a non-T-cell leukemia antigen preparation isolated from cell membranes of leukemia cells derived from a patient (FJ) with non-T/non-B-cell-type acute lymphoblastic leukemia (ALL). SN6 was tested against a variety of cultured and uncultured human cell specimens by using a sensitive cellular radioimmunoassay. Among the 26 cultured malignant and nonmalignant cell lines tested, SN6 reacted with all of the 6 leukemic non-T/non-B (including pre-B)-cell lines tested-i.e., KM-3, NALM-16, REH, NALL-1, NALM-1, and NALM-6. Of these cell lines, 5 were derived from individual patients with ALL; the remaining 1 was from a patient with chronic myelocytic leukemia in blast crisis. In addition, SN6 reacted with 3 of 3 leukemic myelo-monocytic cell lines tested-i.e., ML-2, HL-60, and U937. SN6 did not react with any other cell lines. A consistent result was obtained with 42 fresh (uncultured) cell specimens derived from individual patients with several different types of leukemias. SN6 reacted with 11 of 16 non-T/non-B (including pre-B)-cell ALL specimens. In addition, it reacted with various myelo-monocytic leukemia cell specimens to various degrees. SN6 did not show a significant reaction with normal peripheral blood cells tested, which included B cells, T cells, granulocytes, monocytes, and erythrocytes. However, it reacted with a small population (-1 % as determined by immunofluorescence staining) of normal bone marrow cells. The approximate molecular mass of the glycoprotein antigen defined by SN6 was determined to be 160,000 by radioimmunoprecipitation followed by sodium dodecyl sulfate/polyacrylamide gel electrophoresis. Only one component of 80,000 daltons was formed upon reduction of the 160,000 molecular mass antigen. Therefore, this antigen is apparently a homodimer of a 80,000-dalton subunit. This conclusion was further corroborated by two-dimensional gel analysis, which showed a single well-defined spot for the reduced antigen. We designate this distinct human leukemiaassociated cell surface antigen "GP160."

show abstract

Section: Discussionmentioning

confidence: 99%

Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6.

Haruta¹,

Seon²

1986

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…Cancer among persons exposed as children to the atomic bomb is only now beginning to appear (27), and types of cancer other than leukemia have a distinctly longer latent period among the spondylitic population. Evans has noted that the latent period is inversely related to body burden of radium among radium dial painters (28).…”

Section: Radiological Effectsmentioning

confidence: 99%

Human Costs of Nuclear Power

Sagan

1972

Science

View full text Add to dashboard Cite

“…From the Japanese atomic bomb survivors, data reported by Sampson et al (1969) show that about 18 % of those selected for a life-span study who come to autopsy have primary thyroid cancers, as diagnosed by serial section of the thyroid. In the selected group of survivors who were in the 0-10 years age group at the time of the bomb (Jablon et al 1971), thyroid cancer incidence at present appears to be about equal to the leukaemia incidence. In older age groups thyroid cancer is less evident and this may indicate a higher sensitivity to radiation-induced thyroid cancer in young people.…”

mentioning

confidence: 94%

Evidence in Man of Radiation Carcinogenesis of the Thyroid

Dolphin¹

1974

Proceedings of the Royal Society of Medicine

View full text Add to dashboard Cite

Maintenance of considerably raised endogenous secretion of TSH in experimental animals for half or more of their life-span leads to the development of thyroid follicle cell adenomas and carcinomas. The varied regimens used have been iodine deficient diets, goitrogenic drugs, subtotal thyroidectomy.The yield of tumours in rats is considerably enhanced by pretreatment with ionizing radiation to the thyroid, external X-radiation or radioactive iodine. Radiation on its own in doses of 1000 rad X-rays or 10-50 ,uCi of 1131 initiates neoplastic changes and, by diffuse radiation damage to the thyroid gland, leads to a rise in endogenous secretion of TSH that promotes tumour development.Occasional follicle cell tumours arise 1i to 2 years after small doses of radiation, 100 rad X-rays or 1 ,uCi of 1311, in the absence of any maintained rise in TSH.

show abstract

Noise and Hearing

Cited by 3 publications

References 0 publications

Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6.

Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6.

Human Costs of Nuclear Power

Evidence in Man of Radiation Carcinogenesis of the Thyroid

Contact Info

Product

Resources

About